tiprankstipranks
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
PremiumThe FlyY-mAbs Therapeutics price target lowered to $14 from $17 at BofA
11d ago
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
Premium
Stock Analysis & Ideas
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
1M ago
Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
Premium
The Fly
Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
1M ago
Y-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c)
PremiumThe FlyY-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c)
2M ago
Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
Premium
The Fly
Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
2M ago
Is YMAB a Buy, Before Earnings?
Premium
Pre-Earnings
Is YMAB a Buy, Before Earnings?
2M ago
Cantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals
PremiumThe FlyCantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals
5M ago
Y-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Y-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100